Dr. Raymond Salemme Joins BioLeap's Advisory Board

NEW HOPE, Pa.--(Business Wire)--
"Dr. Salemme is broadly recognized in the pharmaceutical industry
as a business leader and entrepreneur with deep expertise in the
application of crystallography and structure-based design to drug
discovery and, more broadly, to molecular research. We are excited by
the opportunity to benefit from Ray's experience and guidance at
BioLeap in building a capital-efficient business leveraging our new
techniques in moiety-based design of novel therapeutic compounds,"
commented Dr. John Kulp, CEO of BioLeap. "I am delighted to have the
opportunity to work with BioLeap. They have a great team that has
developed a streamlined approach to structure-based drug design that
can be leveraged to a variety of business models," commented Dr.
Raymond Salemme.

Dr. Salemme is currently the CEO of Redpoint Bio. Previously Dr.
Salemme was the founder, President and Chief Scientific Officer of
3-Dimensional Pharmaceuticals, Inc. (3DP), a publicly traded
biotechnology company founded in 1993, and acquired by Johnson &
Johnson in 2003. Dr. Salemme established and directed the technical,
operating, business and financing strategies leading to 3DP's
successful IPO in 2000, and was co-inventor on 30 of 3DP's key
technology patents. Dr. Salemme received the Ernst & Young
Entrepreneur of the Year Award for Greater Philadelphia in 1998 for
his role in building 3DP.

Prior to 3DP, Dr. Salemme directed research groups for biophysics,
computational chemistry, and structure-based drug design at Sterling
Winthrop Pharmaceuticals and DuPont Merck Pharmaceuticals. Dr. Salemme
was Professor of Chemistry and Biochemistry at the University of
Arizona, where he worked in the area of structural proteomics and
determined the 3D X-ray structures of several redox proteins.

Dr. Salemme holds a BA in Molecular Biophysics from Yale
University and a PhD in Chemistry from the University of California at
San Diego.

About BioLeap:

BioLeap is a leader in computational moiety-based drug design. The
company's proprietary design technology and process successfully
addresses one of the biggest problems in pre-clinical drug discovery:
limited chemical diversity of compound libraries. Externally BioLeap
provides highly cost effective lead identification and optimization
services. Internally BioLeap has lead compounds in four development
programs focusing on a broad spectrum anti-bacterial, hepatitis-C and
an inflammation.

BioLeap
Gerry Evans, EVP
215-371-2874
ghe@bioleap.com

Copyright Business Wire 2008